Evidence map›Paper›PMID 31072216›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2019

Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.

Shaymaa E Kassab, Samar Mowafy, Aya M Alserw, Joustin A Seliem, Shahenda M El-Naggar, Nesreen N Omar, Mohamed M Awad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecular design, synthesis andJournal of enzyme inhibition and medicinal chemistry · 2021
    Article
  4. Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells.Journal of enzyme inhibition and medicinal chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Shaymaa E Kassaba Pharmaceutical Chemistry Department, Faulty of Pharmacy , Damanhour University , Damanhour , Egypt.
Samar Mowafyb Pharmaceutical Chemistry Department, Faculty of Pharmacy , Misr International University , Cairo , Egypt.
Aya M Alserwc Basic Research Unit, Department of Research , Children's Cancer Hospital in Egypt , Cairo , Egypt.
Joustin A Seliemc Basic Research Unit, Department of Research , Children's Cancer Hospital in Egypt , Cairo , Egypt.
Shahenda M El-Naggarc Basic Research Unit, Department of Research , Children's Cancer Hospital in Egypt , Cairo , Egypt.
Nesreen N Omard Biochemistry Department, Faculty of Pharmacy , Modern University for Technology and Information , Cairo , Egypt.
Mohamed M Awade Department of Pharmacology and Toxicology, Faculty of Pharmacy , Helwan University , Cairo , Egypt.
Children Cancer Hospital · EGDamanhour University · EGHelwan University · EGMisr International University · EGModern University for Information and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity against HDAC6 targeting solid tumours. Interestingly, 1-benzylbenzimidazole-2-thio-N-hydroxybutanamide 10a showed impressive preference with submicromolar potency against HDAC6 (IC

Indexed as

Drug DesignAntineoplastic AgentsCarcinomaCell Line, TumorCell ProliferationChoroid Plexus NeoplasmsDose-Response Relationship, DrugDrug Screening Assays, AntitumorHistone Deacetylase 6Histone Deacetylase InhibitorsHumansHydroxamic AcidsMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase InhibitorsHydroxamic Acidsacetylated-α-tubulinacute promyeloblastic leukemiabenzimidazolechoroid plexus carcinomacytotoxicityon-target activityPreferential HDAC6 inhibitor

Identifiers

PMID31072216
PMCPMC6522981
OpenAlexW2944370167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.